MarketLens
Sign Up

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

6 months ago
SHARE THIS ON:

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News2 days ago

Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment

Ionis Pharmaceuticals won FDA approval for ZANVASTRO, the first disease-modifying treatment for Alexander disease, an ultra-rare GFAP-related neurological disorder. The approval opens a new commercial...
Stock News1 months ago

Ionis Pharmaceuticals: The Heartbreak Is Priced In

Ionis Pharmaceuticals fell sharply after ATTR-CM and tominersen setbacks, but core assets remain intact. Tryngolza leads value with strong sHTG data; $1.9B liquidity supports a path to 2028 breakeven.
Stock News1 months ago

Can Biogen Score Another Win In Alzheimer's Disease?

Biogen and Ionis' tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months, potentially adding a new therapy to Biogen's pipeline after its earlier Aduhelm struggles.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

Did Nvidia Just Say Checkmate to AMD and Intel?

Stock News4 hours ago

Amazon cargo plane overshoots runway at Miami airport

Stock News4 hours ago

Amazon Prime Air Boeing 767 overruns runway at Miami airport

Stock News4 hours ago

Could $10,000 Invested in Nvidia Today Make You a Millionaire?

Stock News6 hours ago

Nvidia Is Near Its High While Its Biggest Chip Peers Sit 18% to 32% Below Theirs. These Are the Chip Stocks to Buy.